This mechanistic dichotomy necessitates risk-stratified approaches: periodontitis-only patients may benefit from localized NSAID delivery (0.3% flurbiprofen gel) without systemic exposure [12]; AAA-affected individuals require strict avoidance of NSAIDs given accelerated aneurysm expansion rates (+0.8 mm/year) in users [82]; and high-risk comorbid cases should prioritize IL1B blockade via canakinumab (150 mg subcutaneously every 3 months), which demonstrated 15% cardiovascular event reduction in the CANTOS trial without compromising vascular integrity [83]. The gene discussed is IL1B; the disease is periodontitis.